StockData

Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.81+0.13 (+4.85%)

Close on Nov 19, 2026Market cap $188.72MP/E –Yield –

Liminatus Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Liminatus Pharma's R&D Expenses for the twelve months ending Dec 31, 2024 was $2.69M. For fiscal 2024 it was $2.69M.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$2.69M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$600.00K-16.0%
Q1 FY2026Mar 31, 2026$400.00K–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$357.07K–
Q2 FY2024Jun 30, 2024$714.13K–

More Liminatus Pharma figures

See a number that looks wrong?